The PI3K/AKT/mTOR pathway is the most frequently activated oncogenic signalling axis in human cancer, altered in over 70% of tumours through diverse mechanisms: PIK3CA hotspot mutations, PTEN loss, AKT1 E17K mutation, HER2 amplification, or upstream RTK overexpression. This pathway governs cell survival, growth, and metabolism by generating the lipid second messenger PIP3, which recruits and activates AKT, which then activates mTOR. The extraordinary frequency of pathway activation and the availability of multiple approved inhibitors (alpelisib, capivasertib, everolimus) make this the most drugged signalling network in oncology.
RTK activation recruits the PI3Kα heterodimer (p110α–p85) to the membrane, where p110α phosphorylates PIP2→PIP3. PTEN opposes this reaction by dephosphorylating PIP3→PIP2. PIP3 recruits AKT via its PH domain; PDK1 phosphorylates AKT Thr308 and mTORC2 phosphorylates Ser473 for full AKT activation. AKT then phosphorylates >100 substrates — including TSC2 (activating mTORC1), MDM2 (degrading p53), BAD (blocking apoptosis), and GSK3β (stabilising MYC) — creating a central proliferative and survival nexus.
RTK activation recruits the PI3Kα heterodimer (p110α–p85) to the membrane, where p110α phosphorylates PIP2→PIP3. PTEN opposes this reaction by dephosphorylating PIP3→PIP2. PIP3 recruits AKT via its PH domain; PDK1 phosphorylates AKT Thr308 and mTORC2 phosphorylates Ser473 for full AKT activation. AKT then phosphorylates >100 substrates — including TSC2 (activating mTORC1), MDM2 (degrading p53), BAD (blocking apoptosis), and GSK3β (stabilising MYC) — creating a central proliferative and survival nexus.
PI3K / AKT / mTOR Pathway
AKT-mediated TSC2 inactivation allows RHEB-GTP to activate mTORC1 at the lysosomal surface. mTORC1 phosphorylates S6K1 (Thr389) and 4EBP1 (multiple sites), driving ribosome biogenesis and cap-dependent translation of growth-promoting mRNAs.
S6K1 activated by mTORC1 phosphorylates IRS-1 at inhibitory serine residues, reducing insulin receptor→PI3K signal. This negative feedback limits pathway amplitude but paradoxically activates AKT when mTORC1 is blocked by rapamycin/everolimus — the mechanistic basis for compensatory AKT activation on mTOR inhibitors.
PIK3CA mutations occur in ~30% of HR+ breast cancers and are the most common actionable oncogenic alteration in this disease. PTEN loss affects ~30% of glioblastomas and prostate cancers. The pathway drives cancer through four core mechanisms: AKT-mediated apoptotic resistance (BAD phosphorylation), mTORC1-driven protein synthesis and proliferation, MDM2-mediated p53 suppression, and FOXO3a inhibition preventing pro-apoptotic gene expression.
Alpelisib (PI3Kα inhibitor) + fulvestrant is approved for PIK3CA-mutant HR+/HER2− breast cancer. Capivasertib (pan-AKT inhibitor) + fulvestrant is approved for AKT1/PIK3CA/PTEN-altered HR+ breast cancer. Everolimus (mTORC1 inhibitor) is approved for RCC, breast cancer, and pancreatic NETs but causes paradoxical AKT activation via IRS-1 feedback relief. Dual PI3K/mTOR inhibitors (gedatolisib) aim to block both arms simultaneously.
Why does mTOR inhibition with everolimus activate AKT paradoxically?
mTORC1 → S6K1 → IRS-1 creates a negative feedback loop: S6K1 phosphorylates IRS-1 at inhibitory serines, reducing PI3K recruitment to the insulin receptor. When everolimus blocks mTORC1/S6K1, this feedback is relieved, allowing stronger PI3K→AKT signalling. The result is AKT Thr308 phosphorylation and FOXO3a activation — potentially opposing the antiproliferative effect of mTOR inhibition.
What distinguishes alpelisib from pan-PI3K inhibitors?
Alpelisib (BYL719) selectively inhibits PI3Kα (p110α), the isoform encoded by PIK3CA. Pan-PI3K inhibitors that also block PI3Kδ (enriched in lymphocytes) cause dose-limiting immune suppression and colitis. Alpelisib's PI3Kα selectivity reduces immunological toxicity while targeting the specific isoform mutated in breast cancer — the basis for its superior therapeutic index in PIK3CA-mutant disease.
DNA Damage Response Genes
Every human cell sustains approximately 70,000 DNA damage events per day, ranging from base oxidations and replication e…
Cell Cycle Regulation Genes
Cell division is governed by a biochemical oscillator built from cyclin-dependent kinases (CDKs) and their cyclin regula…
Apoptosis Regulators
Apoptosis — programmed cell death — is the cell's ultimate tumour-suppressive mechanism, eliminating cells with irrepara…
RAS/MAPK Signalling Pathway
The RAS/RAF/MEK/ERK (MAPK) cascade is one of the most ancient and conserved proliferative signalling pathways in eukaryo…
Content is based on peer-reviewed scientific literature including data from NCBI, UniProt, PubMed, and TCGA. Gene links reference curated molecular biology databases. For educational purposes only; does not constitute clinical advice.